Bio-techne Corporation Intrinsic Stock Value – State of Alaska Department of Revenue Reduces Stake in Bio-Techne Corporation

🌥️Trending News

BIO-TECHNE ($NASDAQ:TECH): Bio-Techne Corporation is a biotechnology company that develops and manufactures products for research and clinical diagnostic markets. The company provides tools and reagents, such as antibodies, proteins, and peptides, to scientists and researchers in the life sciences industry, enabling the advancement of medical research. The State of Alaska Department of Revenue recently announced that it had reduced its stake in Bio-Techne stock. Bio-Techne’s products are used in a number of industries, including biopharmaceuticals, diagnostic, and academic research. The company has also developed products specifically for use in the clinical diagnostics field.

Bio-Techne’s products are used by scientists to study gene expression, cell biology, metabolism, and endocrinology. It has also established partnerships with other organizations, such as the National Institutes of Health (NIH), to develop new products for research. Bio-Techne’s stock is traded on the Nasdaq stock exchange under the symbol “TECH”. Despite this decrease in ownership, the company’s performance has remained strong, driven by its focus on developing new technologies and products.

Earnings

According to the company’s earning report of FY2024 Q1 as of September 30 2021, Total Revenue was reported at 257.72M USD with net income of 69.61M USD. This represented a 4.4% decrease in total revenue and a 22.3% decrease in net income compared to the previous year. However, over the past 3 years, Bio-Techne Corporation‘s total revenue has increased from 257.72M USD to 276.94M USD.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Bio-techne Corporation. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Bio-techne Corporation. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Bio-techne Corporation. More…

Key Ratios Snapshot

Some of the financial key ratios for Bio-techne Corporation are shown below. More…

Market Price

The State of Alaska Department of Revenue recently announced that it has reduced its stake in Bio-Techne Corporation, a leading provider of biological and analytical technologies for life science research, clinical diagnostics and drug discovery. On Tuesday, BIO-TECHNE CORPORATION stock opened at $76.4 and closed at $76.7, down by 0.6% from prior closing price of 77.2. Live Quote…

Analysis – Bio-techne Corporation Intrinsic Stock Value

At GoodWhale, we believe that analyzing fundamentals is the key to finding true value in stocks. That’s why we’ve taken a deep dive into the fundamentals of BIO-TECHNE CORPORATION to help investors understand its true worth. After running our proprietary Valuation Line, our analysis shows that BIO-TECHNE CORPORATION is currently trading at $76.7, undervalued by a whopping 23.2%. That means our fair value estimate for BIO-TECHNE CORPORATION is around $99.9. By taking a closer look at the fundamentals of this company, investors could potentially make a good return on their investment. More…

Peers

In the realm of biotechnology, there is fierce competition between companies to provide the best products and services. Among these companies is Bio-Techne Corp, which competes against Proteomics International Laboratories Ltd, AEterna Zentaris Inc, AXIM Biotechnologies Inc, and others. While each company has its own strengths and weaknesses, Bio-Techne Corp has been able to distinguish itself through its innovative products and cutting-edge technology. As the biotechnology landscape continues to evolve, it will be interesting to see how these companies adapt and change in order to stay ahead of the competition.

– Proteomics International Laboratories Ltd ($ASX:PIQ)

Proteomics International Laboratories Ltd is a company that specializes in providing proteomics services. Its market cap as of 2022 was 110.87M, and its ROE was -75.41%. The company’s main services include proteomics research, biomarker discovery, and protein quantification. Proteomics International Laboratories Ltd has a strong focus on quality and customer service, and has a team of experienced scientists that are dedicated to helping their clients achieve success.

– AEterna Zentaris Inc ($TSX:AEZS)

Aeterna Zentaris is a Canadian biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic drugs for the treatment of cancer and endocrine disorders. As of 2022, the company had a market capitalization of $25.01 million and a return on equity of -14.54%. The company’s products include the cancer drug Macrilen, which is approved for the treatment of acromegaly, and the endocrine disorder drug Zoptarelin Doxorubicin, which is in clinical development for the treatment of breast cancer.

– AXIM Biotechnologies Inc ($OTCPK:AXIM)

AXIM Biotechnologies Inc is a clinical stage pharmaceutical company focused on the development of cannabinoid-based therapeutics. The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions.

The company’s market cap is 10.55M as of 2022. The company’s ROE is 223.83%.

The company’s products are based on proprietary technology platforms that utilize purified cannabinoids to address specific disease conditions. The company is focused on the development of cannabinoid-based therapeutics to treat pain, inflammation, anxiety, and other conditions.

Summary

Bio-Techne Corporation is a publicly traded biotechnology company focused on developing and selling biopharmaceuticals, proteins, and antibodies. Recently, the State of Alaska Department of Revenue has lessened their stake in Bio-Techne Corporation. This news has caused some investors to question the company’s future growth prospects. Analysts believe that Bio-Techne Corporation is still a sound long-term investment, due to its strong financials, diverse product portfolio, and proven leadership.

However, some investors are concerned about the potential for future political uncertainty and lack of control over their investments. In the short-term, investors should monitor the company’s stock price movements and earnings announcements to make sure their investments are sound.